Literature DB >> 2644640

Cardiac allograft survival in mice treated with IL-2-PE40.

H Lorberboum-Galski1, L V Barrett, R L Kirkman, M Ogata, M C Willingham, D J FitzGerald, I Pastan.   

Abstract

IL-2-PE40 is a chimeric protein composed of human interleukin 2 (IL-2) genetically fused to the amino terminus of a modified form of Pseudomonas exotoxin lacking its cell recognition domain. IL-2-PE40, which is extremely cytotoxic to IL-2 receptor-positive cells, was examined for its ability to prevent graft rejection in mice in which activation of T cells is prominent. We demonstrate that intraperitoneally administered IL-2-PE40 specifically and significantly prolongs the survival of vascularized heart allografts in mice. The chimeric toxin, IL-2-PE40, offers an alternative approach to the treatment of autoimmune diseases and transplant rejection in humans.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2644640      PMCID： PMC286610          DOI： 10.1073/pnas.86.3.1008

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   12.779


  35 in total

1.  Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion protein.

Authors:  J R Murphy; W Bishai; M Borowski; A Miyanohara; J Boyd; S Nagle
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

2.  Monoclonal anti-IL-2 receptor antibody in primate renal transplantation.

Authors:  M E Shapiro; R L Kirkman; M H Reed; J D Puskas; G Mazoujian; N L Letvin; C B Carpenter; E L Milford; T A Waldmann; T B Strom
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

3.  Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal antibody therapy.

Authors:  J W Kupiec-Weglinski; H J Hahn; R L Kirkman; H D Volk; A Mouzaki; R DiStefano; G Tellides; M Dallman; P J Morris; T B Strom
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

4.  Functional blocking of the interleukin-2 receptor (IL-2R) may be important in the efficacy of IL-2R antibody therapy.

Authors:  G Tellides; M J Dallman; J W Kupiec-Weglinski; T Diamantstein; P J Morris
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

5.  Prolongation of rat pancreatic islet allograft survival by treatment of recipient rats with monoclonal anti-interleukin-2 receptor antibody and cyclosporin.

Authors:  H J Hahn; B Kuttler; A Dunger; I Klöting; S Lucke; H D Volk; R von Baehr; T Diamantstein
Journal:  Diabetologia       Date:  1987-01       Impact factor: 10.122

6.  Islet allograft survival after a single course of treatment of recipient with antibody to L3T4.

Authors:  J A Shizuru; A K Gregory; C T Chao; C G Fathman
Journal:  Science       Date:  1987-07-17       Impact factor: 47.728

7.  Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli.

Authors:  H Lorberboum-Galski; D FitzGerald; V Chaudhary; S Adhya; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

8.  Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein.

Authors:  P Bacha; D P Williams; C Waters; J M Williams; J R Murphy; T B Strom
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

9.  Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin.

Authors:  V K Chaudhary; D J FitzGerald; S Adhya; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 12.779

10.  Exotoxin A of Pseudomonas aeruginosa: substitution of glutamic acid 553 with aspartic acid drastically reduces toxicity and enzymatic activity.

Authors:  C M Douglas; R J Collier
Journal:  J Bacteriol       Date:  1987-11       Impact factor: 3.476
View more
  5 in total

1.  A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin.

Authors:  V K Chaudhary; M G Gallo; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 2.  Immunotherapy through the IL-2 receptor.

Authors:  H A Verheul; M Verveld; E S Bos
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

3.  Effect of IL-2-Bax, a novel interleukin-2-receptor-targeted chimeric protein, on bleomycin lung injury.

Authors:  Michael J Segel; Rami Aqeilan; Keren Zilka; Haya Lorberboum-Galski; Shulamit B Wallach-Dayan; Michael W Conner; Thomas G Christensen; Raphael Breuer
Journal:  Int J Exp Pathol       Date:  2005-10       Impact factor: 1.925

4.  Cytokines in clinical and experimental transplantation.

Authors:  A C Vossen; H F Savelkoul
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

5.  Transforming growth factor alpha-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts.

Authors:  D C Heimbrook; S M Stirdivant; J D Ahern; N L Balishin; D R Patrick; G M Edwards; D Defeo-Jones; D J FitzGerald; I Pastan; A Oliff
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 12.779
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.